Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients with Ovarian and Metastatic Breast Cancer - SOLI

Study identifier:D0816R00025

ClinicalTrials.gov identifier:NCT04330040

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation

Medical condition

ovarian cancer

Phase

Phase 4

Healthy volunteers

No

Study drug

Olaparib

Sex

Female

Actual Enrollment

202

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 25 May 2020
Primary Completion Date: 30 Sept 2022
Study Completion Date: 30 Sept 2022

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria